[The importance of concurrent therapy with insulin and sulfonylurea derivatives in type II diabetes].
The author presents an account of combined treatment with insulin and sulphonylurea derivatives in 46 diabetics type 2 for a period of three years. In all patients satisfactory metabolic compensation was achieved which persisted throughout the whole period at a level of HbA1c values of 8.0-8.5%. The author considers combined treatment indicated in secondary failure of oral antidiabetics with preserved C peptide secretion of 0.8-0.24 ng/ml. Combined treatment may be also a solution for some metabolically unbalanced diabetes type 2 with obesity and hyperinsulinaemia. Combined treatment is useful, does not burden the patient with large insulin doses and proves useful also in long-term satisfactory compensation as it reduces the risk of development of complications. Combined treatment fails in 9.6% of the patients, usually during the first year.
Podrouzková
B
B
II. interní klinika LF Masarykovy univerzity.
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*
D007328:Insulin; D013453:Sulfonylurea Compounds
Význam soucasné lécby inzulin/deriváty sulfonylmocoviny u diabetu II. typu (NIDDM).